Onco Actu du 2 octobre 2019

	1. BIOLOGIE
How cancer vesicles breach the blood-brain barrier [NIH] Researchers discovered how small particles from cancer cells called extracellular vesicles cross the blood-brain barrier to make the brain more hospitable to metastatic tumors.
	2.6 ETIOLOGIE - ENVIRONNEMENT
Can herbicides cause breast cancer? Purdue and INSERM scientists discover a piece to the puzzle. [Purdue University] Scientists exposed noncancerous human mammary epithelial cells to glyphosate in vitro over a course of 21 days. The cells were then placed in mice to assess tumor formation. Although cells exposed to glyphosate alone did not induce tumor growth, cancerous tumors did develop after glyphosate was combined with molecules that were linked to oxidative stress. The work was published in Frontiers in Genetics.
	3.1.1 PRÉVENTION - TABAC - E-CIGS
Mysterious vaping deaths: Why US officials are focusing on flavour [Nature] As lung injuries among e-cigarette users mount amid a youth vaping epidemic, the impact of new restrictions remains unclear.
	3.8 PRÉVENTION - ALIMENTATION
Foods High in Vitamin A May Help Ward Off Skin Cancer [NY Times] The researchers, writing in JAMA Dermatology, used detailed health and diet data from 123,570 men and women participating in two long-term studies. They found 3,978 cases of squamous cell cancer over more than 26 years of follow-up.
	4. DÉPISTAGE, DIAGNOSTIC ET PRONOSTIC
What is overdiagnosed cancer? And why does it matter? [Croakey] Evidence-based medicine expert Professor Paul Glasziou cautions in the article below that patients, doctors and Health Ministers must understand the limitations of screening “if we are to avoid an epidemic of overdiagnosis”.
	4.10 DÉP., DIAG. & PRONO. - POUMON
Screening for lung cancer based on risk could save lives [University of Michigan] Current lung cancer screening is based on age (ages 55 to 80), on how much individuals have smoked (measured as pack-years), and how long they have stopped smoking. The team looked at various risk-prediction models that consider behavior, lifestyle and family history to estimate the probability of getting or dying from lung cancer. CISNET published its findings this week in the Journal of the National Cancer Institute.
	5.12.11 IMMUNOTHÉRAPIES - PRÉ-CLINIQUE
A promising antibody [Kiel University] The research team carried out fundamental combination experiments on mice using the antibody daratumumab to test for possible effectiveness against T-ALL cancer cells. In doing so, they also compared antibody treatment alone with a combination of antibody and chemotherapy.
	5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES
Cellectis and Lonza Enter cGMP Manufacturing Service Agreement for Cellectis’ Allogeneic UCART Product Candidates [Cellectis] Manufacturing to take place at Lonza's GMP site in Geleen, Netherlands.
	5.12.5 IMMUNOTHÉRAPIES - PHARMA
ElevateBio founds HighPassBio to develop Fred Hutch cell therapy [Fierce Biotech] ElevateBio has founded HighPassBio to advance T-cell immunotherapies based on research from the Fred Hutchinson Cancer Research Center. HighPassBio starts life with a phase 1 leukemia cell therapy and the support of a founder that recently raised $150 million to build a portfolio of startups.
	5.17 TRAITEMENTS - RADIOTHÉRAPIE
Gut bacteria ‘fingerprint’ predicts radiotherapy side effects [Imperial College London] Their study, published in Clinical Cancer Research, aimed to see if there was a difference in the combination of gut bacteria among patients who suffered gut damage following radiotherapy compared with those who didn’t.
	5.2 PHARMA
Sanofi's story needs to be 'better told,' new CEO says [Biopharma Dive] In oncology and blood diseases, Sanofi will be hard-pressed to stay competitive.
	5.3 TRAITEMENTS - FDA, EMA, NICE...
Trump set to nominate Stephen Hahn as FDA commissioner, pending vetting process [STAT] The Trump administration’s decision goes against the advice of four former FDA commissioners and an array of advocacy organizations, all of which had called for Sharpless to be named the permanent agency head.
Patient-focused drug development: New FDA draft guidance delves into what’s important [EndPoints] In determining what’s important, the FDA recommends that sponsors use qualitative research methods, which can generate in-depth thoughts from patients in their own words through interviews or focus groups, quantitative research methods, which can use statistical methods to summarize the collective patient experience data, or mixed-methods research, which can combine qualitative and quantitative methods to understand the patient experience.
Trump will pick Stephen Hahn as his next FDA commissioner — reports [EndPoints] Hahn, the chief medical officer at MD Anderson in Houston and a radiation oncologist by training, is a longtime Republican donor who has given to Mitt Romney, John McCain, and George W Bush, among others, but not Trump. Sharpless has exclusively contributed money to Democrats.
	5.6 ESMO
ESMO 2019 may be over, but the market battles it set up are just getting started [Fierce Pharma] The conference, which has been gaining steam in recent years thanks to the sheer volume of oncology data proliferating in the immuno-oncology era, was arguably as significant as it's been to date, hosting a number of data presentations that marked important “firsts” in the cancer field.
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More [Xconomy] We’ll bring you the latest results from PARP trials, as well as news about breast cancer, the suddenly hot target known as KRAS, a boost for the Northwest’s biggest biopharma company, and more.
	5.6.13 ESMO - PROSTATE
First Prostate Cancer Therapy to Target Genes Delays Cancer Progression [Northwestern University] This marks a significant advance for prostate cancer treatment, which has lagged behind other common cancers with regard to precision therapy, now the standard of care in breast, ovarian and lung cancers.
Esmo 2019 – Clovis is running out of waves to catch [Vantage] In prostate cancer Clovis could be adopting a more realistic regulatory stance with its Parp than Astrazeneca and Merck & Co. In the long run will it matter much?
	6.6 PUBLICATIONS
Two-thirds of researchers report ‘pressure to cite’ in Nature poll [Nature] Readers say they have been asked to reference seemingly superfluous studies after peer review.
	6.7.1 IA/BIOINFORMATIQUE
Bringing together deep bioscience and AI to help patients worldwide: Novartis and Microsoft work to reinvent treatment discovery and development [Microsoft] Novartis and Microsoft are collaborating to explore how to take advantage of advanced Microsoft AI technology combined with Novartis’ deep life sciences expertise to find new ways to address the challenges underlying every phase of drug development – including research, clinical trials, manufacturing, operations and finance.